GlassScriptPhysician profile
Ming-Kong Liu
NPI 1205927191
$6,384.57
in general payments reported to CMS, 2019-2025
53 companies · $846 in 2025
The $846 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,188 · 2020: $883 · 2021: $984 · 2022: $1,091 · 2023: $783 · 2024: $609 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,238.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $617.29 | 2019-2025 | Jardiance, Ofev, Cyltezo |
| Glaxosmithkline, LLC. | $554.87 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Actelion Pharmaceuticals US, INC. | $406.09 | 2019-2025 | Opsumit |
| Novo Nordisk INC | $400.37 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Mylan Specialty L.P. | $370.49 | 2019-2024 | Yupelri |
| Insmed, INC. | $264.64 | 2019-2025 | Arikayce, Brinsupri |
| Lilly USA, LLC | $254.84 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $238.29 | 2019-2024 | Farxiga |
| Teva Pharmaceuticals USA, INC. | $228.23 | 2020-2022 | |
| Amgen INC. | $207.01 | 2022-2025 | Evenity, Prolia, Krystexxa |
| Abbvie INC. | $205.58 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $183.82 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $175.96 | 2019-2024 | |
| Pulmonx Corporation | $175.32 | 2022 | |
| Grifols USA, LLC | $153.75 | 2019-2025 | Prolastin-C Liquid |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ming-Kong Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.